Navigation Links
Professor Sir Martin Evans wins Nobel Prize for Medicine
Date:10/9/2007

ears ahead.

The Vice-Chancellor of Cardiff University, Dr David Grant, said: Cardiff University is delighted to join the world-wide congratulations for Sir Martin Evans. The Nobel Prize is tribute not just to the academic brilliance of Sir Martins discoveries, once thought by many to be impossible, but also to the wide-ranging benefits of his research.

As the Nobel Assembly correctly points out, the break-throughs by Sir Martin and his fellow Nobel laureates have generated an explosion of international research activity applying their techniques. Sir Martin himself has developed models for diseases such as human breast cancer, just one of the diseases where our understanding has been revolutionised, offering hope to millions of sufferers around the world.

Professor John Harwood, Head of the School of Biosciences, said: This is fantastic news and clearly is very well deserved. Martins research into stem cells and gene therapy is very important and offers also sorts of promise to medicine.

This is also marvellous news for Cardiff University and Wales. Cardiff improves year on year and this is another accolade for the University. In science it doesn't come any higher than the Nobel Prize.

Professor Sir Martin has been a key figure in establishing Cardiff University as a world-leading centre for biomedical research. The University was listed in the worlds top 100, and the top ten in the UK, for biomedicine in last years Times Higher Educational Supplement World University Rankings.


'/>"/>

Contact: Stephen Rouse
RouseS@cardiff.ac.uk
029-208-75596
Cardiff University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Great White shark evolution debate involves WSU Lake Campus geology professor
2. K-State professors discover enzyme responsible for creation of a beetles hard shell
3. Pitt professors theory of evolution gets boost from cell research
4. DNA conclusive yet still controversial, Carnegie Mellon professor says
5. Professors to develop hand-held pathogen testing device
6. LSU professor discovers new species
7. Outsmarting the smartie bug
8. Papers of DNA Pioneer and Nobel Laureate Francis Crick Added to National Library of Medicine’s Profiles in Science Web Site
9. Nobelist discovers antidepressant protein in mouse brain
10. Comments, experts and background on the 2006 Nobel Prize in chemistry
11. Nobel Laureate finds elegant explanation for DNA transcribing enzymes high fidelity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015  Automation and pre-processing are reducing the ... This is the first step toward a future ... unintrusive. An assortment of portal scanners, biometric collection ... will transform the passenger screening process. ... Airport Passenger Screening Market ( http://www.frost.com/nf2b ), ...
(Date:8/28/2015)... , August 28, 2015 According ... Training Market by Assessment Type (Pen & Paper Based, ... Training, Corporate Learning, Academic Research), Vertical and Region - ... and Training Market to grow from USD 2.4 Billion ... a Compound Annual Growth Rate (CAGR) of 25.6% from ...
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... Chicago Stritch School of Medicine have received a five-year, ... to study vitamin D deficiency in people of African ... vitamin D levels and risks for certain chronic diseases, ... previous studies is "inconclusive and needs to be studied ...
... and the United States recently published their joint findings that ... have a hidden signature. Findings published this month in ... , demonstrate that up to seven months before an animal ... prion protein in the brain was being eradicated. This member ...
... be used to reduce levels of carbon dioxide in the ... suck in carbon dioxide from the air are being developed ... Edinburgh, with funding from the RCUK Energy Programme, led by ... one 1m2 unit containing the tiny tubes could adsorb (suck ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Medical researchers in Canada and the US discover hidden side of prion diseases 2Collecting carbon in a concrete jungle 2
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. ... H. Anderson , president and chief executive officer, will ... Wednesday, September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may ... webcast will be available shortly after conclusion of the ...
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry ... their entire waste to energy process and continue to contribute to the sustainability ... , Temarry’s Waste to Energy process has been operating at their Mexico facility, ...
(Date:9/1/2015)... 2015 Swecure, ein ... und Entwicklung neuartiger Therapien für Störungen des ... Reizdarm konzentriert, erhält vom US Patent and ... Medikament patentiert wird. Das Medikament basiert auf ... verhindert und Entzündungen vorbeugt.   Das ...
Breaking Biology Technology:Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... Bio Base Europe is making,progress in the development of sustainable biofuels. The recent first crop of,genetically modified poplars of the Flemish Institute for Biotechnology (VIB),will be modified ... ... ... ...
... , March 14 /PRNewswire/ -- Results from a landmark study involving more than 9,000 people showed that the high blood pressure ... ... , , ... ...
... MDVN ) today announced that it will host a teleconference and webcast with management to discuss fourth quarter ... 4:30 p.m. Eastern Time . A press release for the fourth quarter and year ended on ... ... ...
Cached Biology Technology:Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 2Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 3NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 2NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 3NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 5NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 6NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 7NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 8NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 9NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 10NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 11NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 12NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 13Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 2Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 3